New developments in carbapenems

Clinical Microbiology and Infection

Volumn 14, Issue 12, 2008, Pages 1102-1111

  Kattan, J N ^a,b   Villegas, M V ^a   Quinn, J P ^b,c,d  

^a CENTRO INTERNACIONAL DE ENTRENAMIENTO E INVESTIGACIONES MÉDICAS CIDEIM   (Colombia)

^b John Stroger Hospital   (United States)

^c Chicago Infectious Disease Research Institute   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Carbapenems; Multidrug resistance; Review; lactams

Indexed keywords

CARBAPENEM DERIVATIVE; CEFOTETAN; DORIPENEM; ERTAPENEM; IMIPENEM; MEROPENEM; PANIPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ABDOMINAL INFECTION; ANTIMICROBIAL ACTIVITY; BACTERIAL INFECTION; BACTERIAL MENINGITIS; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DRUG CHOICE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; HOSPITAL INFECTION; HUMAN; LIVER TOXICITY; MULTIDRUG RESISTANCE; NEPHROTOXICITY; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; PYELONEPHRITIS; RECOMMENDED DRUG DOSE; REVIEW; SKIN INFECTION; URINARY TRACT INFECTION; URTICARIA; VENTILATOR ASSOCIATED PNEUMONIA;

NEGIBACTERIA;

EID: 57649225513     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2008.02101.x     Document Type: Review

References (90)

1. Fritsche TR, Stilwell MG, Jones RN. Antimicrobial activity of doripenem (S-4661): A global surveillance report (2003). Clin Microbiol Infect 2005; 11: 974-984.
2. Bush K. The impact of beta-lactamases on the development of novel antimicrobial agents. Curr Opin Investig Drugs 2002; 3: 1284-1290.
3. Villegas MV, Lolans K, Correa A et al. First detection of the plasmid-mediated class A carbapenemase KPC-2 in clinical isolates of Klebsiella pneumoniae from South America. Antimicrob Agents Chemother 2006; 50: 2880-2882.
4. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
5. Naas T, Levy M, Hirschauer C, Marchandin H, Nordmann P. Outbreak of carbapenem-resistant Acinetobacter baumannii producing the carbapenemase OXA-23 in a tertiary care hospital of Papeete, French Polynesia. J Clin Microbiol 2005; 43: 4826-4829.
6. Suarez CJ, Lolans K, Villegas MV, Quinn JP. Mechanisms of resistance to beta-lactams in some common Gram-negative bacteria causing nosocomial infections. Expert Rev Anti Infect Ther 2005; 3: 915-922.
7. Livermore DM. The threat from the pink corner. Ann Med 2003; 35: 226-234.
8. Deshpande LM, Rhomberg PR, Sader HS, Jones RN. Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: Report from the MYSTIC Program (1999-2005). Diagn Microbiol Infect Dis 2006; 56: 367-372.
9. Deshpande LM, Jones RN, Fritsche TR, Sader HS. Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: Report from the SENTRY Antimicrobial Surveillance Program (2000-2004). Microb Drug Resist 2006; 12: 223-230.
10. Luzzaro F, Docquier JD, Colinon C et al. Emergence in Klebsiella pneumoniae and Enterobacter cloacae clinical isolates of the VIM-4 metallo-beta-lactamase encoded by a conjugative plasmid. Antimicrob Agents Chemother 2004; 48: 648-650.
11. Sader HS, Castanheira M, Mendes RE, Toleman M, Walsh TR, Jones RN. Dissemination and diversity of metallo-beta-lactamases in Latin America: report from the SENTRY Antimicrobial Surveillance Program. Int J Antimicrob Agents 2005; 25: 57-61.
12. Scoulica EV, Neonakis IK, Gikas AI, Tselentis YJ. Spread of bla(VIM-1)-producing E. coli in a university hospital in Greece. Genetic analysis of the integron carrying the bla(VIM-1) metallo-beta-lactamase gene. Diagn Microbiol Infect Dis 2004; 48: 167-172.
13. Yigit H, Queenan AM, Anderson GJ et al. Novel carbapenem-hydrolyzing betalactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001; 45: 1151-1161.
14. Woodford N, Tierno PM Jr, Young K et al. Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A beta-lactamase, KPC-3, in a New York Medical Center. Antimicrob Agents Chemother 2004; 48: 4793-4799.
15. Smith ME, Hanson ND, Herrera VL et al. Plasmid-mediated, carbapenem-hydrolysing beta-lactamase, KPC-2, in Klebsiella pneumoniae isolates. J Antimicrob Chemother 2003; 51: 711-714.
16. Naas T, Nordmann P, Vedel G, Poyart C. Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC in a Klebsiella pneumoniae isolate from France. Antimicrob Agents Chemother 2005; 49: 4423-4424.
17. Lolans K, Rice TW, Munoz-Price LS, Quinn JP. Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40. Antimicrob Agents Chemother 2006; 50: 2941-2945.
18. Villegas MV, Lolans K, Correa A, Kattan JN, Lopez JA, Quinn JP. First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing [beta]-lactamase. Antimicrob Agents Chemother 2007; 51: 1553-1555.
19. Nakano V, Padilla G, do Valle Marques M, Avila-Campos MJ. Plasmid-related beta lactamase production in Bacteroides fragilis strains. Res Microbiol 2004; 155: 843-846.
20. Bonfiglio G, Russo G, Nicoletti G. Recent developments in carbapenems. Expert Opin Investig Drugs 2002; 11: 529-544.
21. Jones RN, Sader HS, Fritsche TR. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms. Diagn Microbiol Infect Dis 2005; 52: 71-74.
22. Villegas MV, Lolans K, del Rosario OM et al. First detection of metallo-beta-lactamase VIM-2 in Pseudomonas aeruginosa isolates from Colombia. Antimicrob Agents Chemother 2006; 50: 226-229.
23. Nishio H, Komatsu M, Shibata N et al. Metallo-beta-lactamase-producing gram-negative bacilli: Laboratory-based surveillance in cooperation with 13 clinical laboratories in the Kinki region of Japan. J Clin Microbiol 2004; 42: 5256-5263.
24. Gales AC, Menezes LC, Silbert S, Sader HS. Dissemination in distinct Brazilian regions of an epidemic carbapenem-resistant Pseudomonas aeruginosa producing SPM metallo-beta-lactamase. J Antimicrob Chemother 2003; 52: 699-702.
25. Livermore DM. Interplay of impermeability and chromosomal beta-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 1992; 36: 2046-2048.
26. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: Our worst nightmare? Clin Infect Dis 2002; 34: 634-640.
27. Okamoto K, Gotoh N, Nishino T. Alterations of susceptibility of Pseudomones aeruginosa by overproduction of multidrug efflux systems, MexAB-OprM, MexCD-OprJ, and MexXY/OprM to carbapenems: Substrate specificities of the efflux systems. J Infect Chemother 2002; 8: 371-373.
28. Sobel ML, Hocquet D, Cao L, Plesiat P, Poole K. Mutations in PA3574 (nalD) lead to increased MexAB-OprM expression and multidrug resistance in laboratory and clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005; 49: 1782-1786.
29. Sobel ML, Neshat S, Poole K. Mutations in PA 2491 (mexS) promote Mex'1′-dependent MexEF-oprN expression and multidrug resistance in a clinical strain of Pseudomonas aeruginosa. J Bacteriol 2005; 187: 1246-1253.
30. Schwaber MJ, Navon-Venezia S, Schwartz D, Carmeli Y. High levels of antimicrobial coresistance among extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2005; 49: 2137-2139.
31. Zhanel GG, Hisanaga TL, Laing NM et al. Antibiotic resistance in Escherichia coli outpatient urinary isolates: Final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents 2006; 27: 468-475.
32. Colardyn F. Appropriate and timely empirical antimicrobial treatment of ICU infections - a role for carbapenems. Acta Clin Belg 2005; 60: 51-62.
33. Sun HK, Kuti JL, Nicolau DP. Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: A report from the OPTAMA Program. Crit Care Med 2005; 33: 2222-2227.
34. Ong CT, Kuti JL, Nightingale CH, Nicolau DP. Emerging Pseudomonas aeruginosa resistance: Implications in clinical practice. Conn Med 2004; 68: 11-15.
35. Richards GA. The therapeutic challenge of gram-negative sepsis: prolonging the lifespan of a scarce resource. Clin Microbiol Infect 2005; 11 (suppl): 18-22.
36. Tellado JM, Wilson SE. Empiric treatment of nosocomial intra-abdominal infections: A focus on the carbapenems. Surg Infect (Larchmt) 2005; 6: 329-343.
37. Kahan JS, Kahan FM, Goegelman R et al. Thienamycin, a new beta-lactam antibiotic. I. Discovery, taxonomy, isolation and physical properties. J Antibiot (Tokyo) 1979; 32: 1-12.
38. Kahan FM, Kropp H, Sundelof JG, Birnbaum J. Thienamycin: Development of imipenen-cilastatin. J Antimicrob Chemother 1983; 12 (suppl): 1-35.
39. Hellinger WC, Brewer NS. Carbapenems and monobactams: Imipenem, meropenem, and aztreonam. Mayo Clin Proc 1999; 74: 420-434.
40. Kropp H, Sundelof JG, Hajdu R, Kahan FM. Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase. Antimicrob Agents Chemother 1982; 22: 62-70.
41. Birnbaum J, Kahan FM, Kropp H, MacDonald JS. Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/ cilastatin. Am J Med 1985; 78: 3-21.
42. Shah PM, Isaacs RD. Ertapenem, the first of a new group of carbapenems. J Antimicrob Chemother 2003; 52: 538-542.
43. Moellering RC Jr, Eliopoulos GM, Sentochnik DE. The carbapenems: New broad spectrum beta-lactam antibiotics. J Antimicrob Chemother 1989; 24 (suppl): 1-7.
44. Chambers HF. Other B-lactam antibiotics. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. Philadelphia, PA: Elsevier Churchill Livingstone, 2005; 311-317.
45. Quale J, Bratu S, Gupta J, Landman D. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2006; 50: 1633-1641.
46. Unal S, Garcia-Rodriguez JA. Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004. Diagn Microbiol Infect Dis 2005; 53: 265-271.
47. Livermore DM, Carter MW, Bagel S et al. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrob Agents Chemother 2001; 45: 1860-1867.
48. John R, Brazier JS. Antimicrobial susceptibility of polymerase chain reaction ribotypes of Clostridium difficile commonly isolated from symptomatic hospital patients in the UK. J Hosp Infect 2005; 61: 11-14.
49. CLSI Breakpoints: CLSI Performance Standards for Antimicrobial Susceptibility Testing; Eighteeth Informational Supplement. CLSI document M100-S18. Wayne, PA: Clinical and Laboratory Standards Institute, 2008.
50. Carbapenems-EUCAST clinical MIC breakpoints 2008-06-19 (v.2.0), http://www.srga.org/eucastwt/MICTAB/MICcarbapenems.html. Last accessed 13 November 2008.
51. Karran SJ, Sutton G, Gartell P, Karran SE, Finnis D, Blenkinsop J. Imipenem prophylaxis in elective colorectal surgery. Br J Surg 1993; 80: 1196-1198.
52. Quinn JP, Dudek EJ, DiVincenzo CA, Lucks DA, Lerner SA. Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections. J Infect Dis 1986; 154: 289-294.
53. Ballestero S, Fernandez-Rodriguez A, Villaverde R, Escobar H, Perez-Diaz JC, Baquero F. Carbapenem resistance in Pseudomonas aeruginosa from cystic fibrosis patients. J Antimicrob Chemother 1996; 38: 39-45.
54. Kohler T, Michea-Hamzehpour M, Epp SF, Pechere JC. Carbapenem activities against Pseudomonas aeruginosa: Respective contributions of OprD and efflux systems. Antimicrob Agents Chemother 1999; 43: 424-427.
55. Vurma-Rapp U, Kayser FH, Hadorn K, Wiederkehr F. Mechanism of imipenem resistance acquired by three Pseudomonas aeruginosa strains during imipenem therapy. Eur J Clin Microbiol Infect Dis 1990; 9: 580-587.
56. Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 2006; 43 (suppl): S49-S56.
57. Zanetti G, Bally F, Greub G et al. Cefepime vs. imipenem for treatment of nosocomial pneumonia in ICU patients: A multicenter, evaluator-blind prospective, randomized study. Antimicrob Agents Chemother 2003; 47: 3442-3447.
58. Bornet C, vin-Regli A, Bosi C, Pages JM, Bollet C. Imipenem resistance of Enterobacter aerogenes mediated by outer membrane permeability. J Clin Microbiol 2000; 38: 1048-1052.
59. Lee EH, Nicolas MH, Kitzis MD et al. Association of two resistance mechanisms in a clinical isolate of Enterobacter cloacae with high-level resistance to imipenem. Antimicrob Agents Chemother 1991; 35: 1093-1098.
60. Rodloff AC, Goldstein EJ, Torres A. Two decades of imipenem therapy. J Antimicrob Chemother 2006; 58: 916-929.
61. Fukasawa M, Sumita Y, Harabe ET et al. Stability of meropenem and effect of 1-beta-methyl substitution on its stability in the presence of renal dehydropeptidase. I. Antimicrob Agents Chemother 1992; 36: 1577-1579.
62. Edwards SJ, Emmas CE, Campbell HE. Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections. Curr Med Res Opin 2005; 21: 785-794.
63. Drusano GL, Hutchison M. The pharmacokinetics of meropenem. Scand J Infect Dis 1995; 96 (suppl): 11-16.
64. Li XZ, Zhang L, Poole K. Interplay between the MexA-MexB-OprM multidrug efflux system and the outer membrane barrier in the multiple antibiotic resistance of Pseudomonas aeruginosa. J Antimicrob Chemother 2000; 45: 433-436.
65. Schmutzhard E, Williams KJ, Vukmirovits G, Chmelik V, Pfausler B, Featherstone A. A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. Meropenem Meningitis Study Group. J Antimicrob Chemother 1995; 36 (suppl): 85-97.
66. Dandekar PK, Maglio D, Sutherland CA, Nightingale CH, Nicolau DP. Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion. Pharmacotherapy 2003; 23: 988-991.
67. Gill CJ, Jackson JJ, Gerckens LS et al. In vivo activity and pharmacokinetic evaluation of a novel long-acting carbapenem antibiotic, MK-826 (L-749,345). Antimicrob Agents Chemother 1998; 42: 1996-2001.
68. Livermore DM, Sefton AM, Scott GM. Properties and potential of ertapenem. J Antimicrob Chemother 2003; 52: 331-344.
69. Keating GM, Perry CM. Ertapenem: A review of its use in the treatment of bacterial infections. Drugs 2005; 65: 2151-2178.
70. Itani KM, Wilson SE, Awad SS, Jensen EH, Finn TS, Abramson MA. Ertapenem versus cefotetan prophylaxis in elective colorectal surgery. N Engl J Med 2006; 355: 2640-2651.
71. Moczygemba LR, Frei CR, Burgess DS. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases. Clin Ther 2004; 26: 1800-1807.
72. Elliot E, Brink AJ, van Greune ZEls J et al. In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum beta-lactamase. Clin Infect Dis 2006; 42: E95-e98.
73. Livermore DM, Mushtaq S, Warner M. Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems. J Antimicrob Chemother 2005; 55: 306-311.
74. Dinubile MJ, Friedland I, Chan CY et al. Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: Observations from two randomized comparative clinical trials of ertapenem therapy. Eur J Clin Microbiol Infect Dis 2005; 24: 443-449.
75. DiNubile MJ, Chow JW, Satishchandran V et al. Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections. Antimicrob Agents Chemother 2005; 49: 3217-3221.
76. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: A multicenter, randomized study. Crit Care Med 2008; 36: 1089-1096.
77. Mori M, Hikida M, Nishihara T, Nasu T, Mitsuhashi S. Comparative stability of carbapenem and penem antibiotics to human recombinant dehydropeptidase-I. J Antimicrob Chemother 1996; 37: 1034-1036.
78. Jones RN, Huynh HK, Biedenbach DJ, Fritsche TR, Sader HS. Doripenem (S-4661), a novel carbapenem: Comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J Antimicrob Chemother 2004; 54: 144-154.
79. Doripenem: S.4661. Drugs R D 2003; 4: 363-365.
80. Jones RN, Huynh HK, Biedenbach DJ. Activities of doripenem (S-4661) against drug-resistant clinical pathogens. Antimicrob Agents Chemother 2004; 48: 3136-3140.
81. Tsuji M, Ishii Y, Ohno A, Miyazaki S, Yamaguchi K. In vitro and in vivo antibacterial activities of S-4661, a new carbapenem. Antimicrob Agents Chemother 1998; 42: 94-99.
82. Ge Y, Wikler MA, Sahm DF, Blosser-Middleton RS, Karlowsky JA. In vitro antimicrobial activity of doripenem, a new carbapenem. Antimicrob Agents Chemother 2004; 48: 1384-1396.
83. Traczewski MM, Brown SD. In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients. Antimicrob Agents Chemother 2006; 50: 819-821.
84. Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: Activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother 2004; 48: 3086-3092.
85. Huynh HK, Biedenbach DJ, Jones RN. Delayed resistance selection for doripenem when passaging Pseudomonas aeruginosa isolates with doripenem plus an aminoglycoside. Diagn Microbiol Infect Dis 2006; 55: 241-243.
86. Kobayashi Y. Study of the synergism between carbapenems and vancomycin or teicoplanin against MRSA, focusing on S-4661, a carbapenem newly developed in Japan. J Infect Chemother 2005; 11: 259-261.
87. Horiuchi M, Kimura M, Tokumura M, Hasebe N, Arai T, Abe K. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics. Toxicology 2006; 222: 114-124.
88. Drusano GL. Prevention of resistance: A goal for dose selection for antimicrobial agents. Clin Infect Dis 2003; 36 (suppl): S42-S50.
89. Merchant S, Gast C, Nathwani D et al. Hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia. Clin Ther 2008; 30: 1-17.
90. Ong CT, Kuti JL, Nicolau DP. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: A report from the OPTAMA Program. Surg Infect (Larchmt) 2005; 6: 419-426.